Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering of 5,227,275 shares of common stock at $0.33 per share, raising approximately $1.7 million in gross proceeds, with additional potential proceeds from unregistered warrants [1][3]. Group 1: Offering Details - The registered direct offering involved 5,227,275 shares priced at $0.33 each, with concurrent private placement of unregistered warrants for the same number of shares at the same exercise price [1]. - The total gross proceeds from the offering are approximately $1.7 million before deducting fees and expenses, with potential additional proceeds of $1.7 million from the unregistered warrants if fully exercised [3]. - The unregistered warrants will be exercisable upon stockholder approval and will expire five years after such approval [1]. Group 2: Regulatory and Legal Aspects - The shares offered in the registered direct offering were made under a "shelf" registration statement filed with the SEC, which became effective on February 10, 2025 [4]. - The unregistered warrants and shares from the private placement were offered under Section 4(a)(2) of the Securities Act and have not been registered, thus cannot be sold in the U.S. without registration or an exemption [5]. Group 3: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [9]. - The company aims to advance medical treatments in areas such as wound healing, multiple sclerosis, and cancer through its innovative cell therapy and tissue regeneration approaches [9].